Partnerships and co-selling for Series A companies: the 90-day install for PE-backed portfolio companies in the Middle East
The exact 90-day plan for standing up partnerships and co-selling at Series A — the point where the founder can no longer be every function. Written for operating partners and portfolio CEOs inside private equity in the Middle East.
This edition of the Growth Broker playbook is written for operating partners and portfolio CEOs inside private equity operating in the Middle East. In this market, Middle Eastern buyers reward in-person credibility, sovereign fit, and patient sequencing, so the way you install partnerships and co-selling has to be shaped to that reality from day one.
Series A is the moment partnerships and co-selling stops being optional. The founder has to step out of some of the work, the plan requires a defensible growth number, and every quarter compounds toward the next raise.
Day 1 to 30: diagnosis and instrumentation. Name the constraint, write the ICP, wire sourced and influenced pipeline from partners into the board pack.
Day 31 to 60: first live cycle at 20% of planned volume. Founder still in every review. Kill criteria written and enforced.
Inside PE-backed portfolio companies, the binding constraint is almost always predictable execution against a hold-period thesis, and in the Middle East it is compounded by the fact that senior-relationship access, not product is what actually gates growth. Partnerships and co-selling is only useful here when it is pointed at both constraints at once.
Day 61 to 90: ramp to full volume, hire the first dedicated operator, and hand off ops. Founder retains strategy and the weekly review.
By day 90 the metric is legible and the trajectory is defensible. This is what turns a Series A story into a Series B round.
Trap most Series A companies fall into: signing MOUs no one operationalises. It usually shows up around day 45 when the founder tries to hire ahead of the model.
The Series A version of partnerships and co-selling looks small compared to what you will build at Series B. That is the point — it is a foundation, not a monument.
Concretely for PE-backed portfolio companies in the Middle East: the portfolio companies that install this hit the next value-creation milestone on schedule, and one sovereign or family-office win in the Middle East justifies a full year of program spend. That is the reason it is worth installing partnerships and co-selling deliberately for this market rather than importing a playbook designed for somewhere else.
Frequently asked questions
Partnerships · PE-backed · Middle East — answered
- Does partnerships and co-selling work for PE-backed portfolio companies in the Middle East?
- Yes — provided it is pointed at predictable execution against a hold-period thesis and adapted to the fact that in the Middle East, Middle Eastern buyers reward in-person credibility, sovereign fit, and patient sequencing. The portfolio companies that install this hit the next value-creation milestone on schedule.
- Should we start partnerships and co-selling before Series A?
- Yes if the founder has time; the Series A version is the same model at higher spend.
- How much of the round should fund partnerships and co-selling?
- Meaningful — often 20–30% of the growth line — but only after diagnosis.
- When do we hire the first partnerships and co-selling operator?
- Around day 60, once the model has run one full cycle with the founder.
- What Series A trap should we avoid?
- Signing MOUs no one operationalises — usually a premature senior hire.
- What is the Middle East-specific pitfall when running partnerships and co-selling for PE-backed?
- Importing a playbook that was built for another market. In the Middle East, Middle Eastern buyers reward in-person credibility, sovereign fit, and patient sequencing — the install has to reflect that.
Growth Broker editorial
Filed under partnerships · pe-backed · middle east